Unknown PHASE2 INTERVENTIONAL 2-arm NCT00707681

Evaluation of Quality of Life and Survival With MS-20 in Patient With Advanced Hepatocellular Carcinoma (FDA IND 74572)

A Phase II Randomized, Controlled Study to Evaluate the Quality of Life, Survival and Therapeutic Benefits of MS-20 in Patient With Advanced Hepatocellular Carcinoma

Sponsor: Microbio Co Ltd

Conditions Hepatocellular Carcinoma

Interventions MS-20 Placebo

Updated 7 times since 2017 Last updated: Feb 24, 2010 Started: Mar 31, 2008 Primary completion: Dec 31, 2010 Completion: Dec 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00707681, this PHASE2 trial focuses on Hepatocellular Carcinoma and remains ongoing. Sponsored by Microbio Co Ltd, it has been updated 7 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE2
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE2
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE2

First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Microbio Co Ltd

Data source: Microbio Co Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Taichung, Taiwan